{"title":"Therapeutics for rheumatic fever and rheumatic heart disease.","authors":"Anna P Ralph, Bart J Currie","doi":"10.18773/austprescr.2022.034","DOIUrl":null,"url":null,"abstract":"<p><p>The goals of acute rheumatic fever therapy are to relieve symptoms, mitigate cardiac valve damage and eradicate streptococcal infection. Preventing future recurrences requires long-term secondary antibiotic prophylaxis and ongoing prevention of Streptococcus pyogenes (group A streptococcus) infections The recommended regimen for secondary prophylaxis comprises benzathine benzylpenicillin G intramuscular injections every four weeks. For patients with non-severe or immediate penicillin hypersensitivity, use erythromycin orally twice daily The goals of therapy for rheumatic heart disease are to prevent progression and optimise cardiac function. Secondary antibiotic prophylaxis can reduce the long-term severity of rheumatic heart disease Patients with rheumatic heart disease, including those receiving benzathine benzylpenicillin G prophylaxis, should receive amoxicillin prophylaxis before undergoing high-risk dental or surgical procedures. If they have recently been treated with a course of penicillin or amoxicillin, or have immediate penicillin hypersensitivity, clindamycin is recommended.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"45 4","pages":"104-112"},"PeriodicalIF":3.4000,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e4/bf/austprescr-45-104.PMC9427630.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Australian Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18773/austprescr.2022.034","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
The goals of acute rheumatic fever therapy are to relieve symptoms, mitigate cardiac valve damage and eradicate streptococcal infection. Preventing future recurrences requires long-term secondary antibiotic prophylaxis and ongoing prevention of Streptococcus pyogenes (group A streptococcus) infections The recommended regimen for secondary prophylaxis comprises benzathine benzylpenicillin G intramuscular injections every four weeks. For patients with non-severe or immediate penicillin hypersensitivity, use erythromycin orally twice daily The goals of therapy for rheumatic heart disease are to prevent progression and optimise cardiac function. Secondary antibiotic prophylaxis can reduce the long-term severity of rheumatic heart disease Patients with rheumatic heart disease, including those receiving benzathine benzylpenicillin G prophylaxis, should receive amoxicillin prophylaxis before undergoing high-risk dental or surgical procedures. If they have recently been treated with a course of penicillin or amoxicillin, or have immediate penicillin hypersensitivity, clindamycin is recommended.
急性风湿热治疗的目标是缓解症状、减轻心脏瓣膜损伤和根除链球菌感染。预防未来复发需要长期的二级抗生素预防和持续预防化脓性链球菌(A 组链球菌)感染。风湿性心脏病的治疗目标是防止病情恶化和优化心脏功能。二次抗生素预防可减轻风湿性心脏病的长期严重程度 风湿性心脏病患者,包括接受苄星青霉素 G 预防治疗的患者,在进行高风险牙科或外科手术前应接受阿莫西林预防治疗。如果他们最近接受过一个疗程的青霉素或阿莫西林治疗,或对青霉素过敏,建议使用克林霉素。
期刊介绍:
Australian Prescriber is Australia''s free, national, independent journal of drugs and therapeutics. It is published every two months online.
Our purpose is to help health professionals make informed choices when prescribing, including whether to prescribe a drug or not. To do this we provide independent, reliable and accessible information.
As well as publishing short didactic reviews, we facilitate debate about complex, controversial or uncertain therapeutic areas.
We are part of NPS MedicineWise, an independent, non-profit organisation providing medicines information and resources for health professionals, and stakeholders involved in the quality use of medicines. NPS MedicineWise is funded by the Australian Government Department of Health.